<DOC>
	<DOCNO>NCT02925247</DOCNO>
	<brief_summary>Direct oral anticoagulant ( DOAC ) , inhibitor factor IIa ( dabigatran ) factor Xa inhibitor ( rivaroxaban , apixaban ) alternative treatment warfarin patient atrial fibrillation ( AF ) non-valvular . These molecule demonstrate non-inferiority compare warfarin standard treatment prevention thromboembolic event patient non-valvular AF high risk thomboembolique ( Score CHA2DS2-VASc ≥1 ) . These molecule constant biological effectiveness require laboratory monitoring clinical practice , unlike AVK whose use require , variability action intra- inter-individual , constant dose adjustment base 'Nationalized Index Ratio ( INR ) . The objective study evaluate interest specific dosage anti-activated factor X activity ( Xa ) identification non-observing treating patient Factor Xa inhibitor patient non-FA valvular</brief_summary>
	<brief_title>Specific Anti Factor Xa Activity Dosage Enhance Detection Nonadherence Atrial Fibrillation Patients</brief_title>
	<detailed_description>Direct oral anticoagulant ( DOAC ) , either factor IIa inhibitor ( dabigatran ) factor Xa inhibitor ( rivaroxaban , apixaban ) alternative vitamin K antagonist patient non-valvular atrial fibrillation ( AF ) . These drug demonstrate non-inferiority , compare warfarin , prevention thromboembolic event high risk ( CHA2DS2-VASc ≥1 ) non-valvular AF patient . These medication predictable pharmacological effect limit drug food interaction relieve need routine anticoagulation monitoring compare warfarin . One limitation drug short half-lives ( 12 hour three drug ) . Thus , single miss dose DOACs regimen may result suboptimal anticoagulation . Adequate adherence DOACs essential achieve effective level anticoagulation . It report 28 % patient treated dabigatan AF poor adherence ( proportion day cover &lt; 80 % ) . In recent study include 500 AF patient , 43 % 44 % , respectively treat VKA DOACs , self-reported non adherence anticoagulation treatment . Lower adherence associate great risk combine all-cause mortality stroke AF patient . The aim study evaluate specific dosage anticoagulation level detect non adherence oral anticoagulant treatment AF patient treat anti factor Xa inhibitor . One hundred fifty consecutive AF patient treat either rivaroxaban 20 mg 15 mg daily apixaban 5 mg 2.5 mg twice daily meet exclusion criterion include study . Planned unplanned admission . Patients ACODs regimen least 30 day inclusion . Informed consent give . Blood sample specific anti factor Xa activity dosage perform . Thereafter , adherence oral anticoagulant treatment evaluate use Morisky medication adherence scale . This 8-item patient self report scale previously validate cardiovascular treatment adherence . Primary endpoint prevalence medication nonadherence base anti factor Xa activity therapeutic level time admission self-reported questionnaire ( Morisky medication adherence scale ) . Secondary endpoint determination prevalence medication nonadherence base self-reported questionnaire ( Morisky medication adherence scale ) , determination predictive factor medication nonadherence population study compare prevalence medication nonadherence base anti factor Xa dose Morisky medication adherence scale .</detailed_description>
	<mesh_term>Atrial Fibrillation</mesh_term>
	<mesh_term>Anticoagulants</mesh_term>
	<criteria>Atrial fibrillation patient age ≥ 18 year . Treated rivaroxaban 20 mg 15 mg daily apixaban 5 mg 2.5 mg twice daily least 4 week . Able provide inform consent . Valvular atrial fibrillation ( i.e . mitral stenosis , valvular prosthesis ) . Pregnancy breast feeding</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2016</verification_date>
</DOC>